3상모집 중단 (진행 중)

Long-term Follow-up Study of Patients Receiving Onasemnogene Abeparvovec-xioi

연구 개요

This is a long-term follow-up safety and efficacy study of participants in clinical trials for spinal muscular atrophy (SMA) who were treated with onasemnogene abeparvovec-xioi. Participants will roll over from their respective previous (parent) study into this long-term study for continuous monitoring of safety as well as monitoring of continued efficacy and durability of response to onasemnogene abeparvovec-xioi treatment.

스폰서
리드: 노바티스
적응증
Spinal Muscular Atrophy Type I, Spinal Muscular Atrophy Type II, Spinal Muscular Atrophy Type III, SMA
중재
Onasemnogene Abeparvovec-xioi
목표 등록
85
시작일
2020-02-10
완료(예정)
2035-12-31

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.